Abstract

Purpose

It seems that 2020 would be always remembered by the name of novel coronavirus (designated as SARS-CoV-2), which exerted its deteriorating effects on the health care, economy, education, and political relationships. In August 2020 more than eight hundred thousand patients lost their lives due to acute respiratory syndrome. In the limited list of therapeutic approaches, the effectiveness of low-dose radiation therapy (LD-RT) for curing inflammatory-related diseases have sparkled a light that probably this approach would bring promising advantages for COVID-19 patients. LD-RT owns its reputation from its ability to modulate the host inflammatory responses by blocking the production of pro-inflammatory cytokines and hampering the activity of leukocytes. Moreover, the cost-effective and availability of this method allow it to be applied to a large number of patients, especially those who could not receive anti-IL-6 treatments in low-income countries. But enthusiasm for applying LD-RT for the treatment of COVID-19 patients has been muted yet.

Conclusion

In this review, we take a look at LD-RT mechanisms of action in the treatment of nonmalignant diseases, and then through studying both the dark and bright sides of this approach, we provide a thorough discussion if LD-RT might be a promising therapeutic approach in COVID-19 patients.

中文翻译：

---

低剂量放疗（CODID-19诱发的肺病）：值得考虑的方法

抽象的

目的

新型冠状病毒（被称为SARS-CoV-2）的名字似乎永远会记住2020年，它对医疗保健，经济，教育和政治关系产生了日益严重的影响。到2020年8月，超过80万患者因急性呼吸道综合症丧生。在有限的治疗方法中，低剂量放射治疗（LD-RT）在治疗炎症相关疾病方面的有效性引起了人们的注意，即该方法可能为COVID-19患者带来有希望的优势。LD-RT通过阻断促炎性细胞因子的产生并阻碍白细胞的活性来调节宿主的炎症反应而享有声誉。而且，这种方法的成本效益和可用性使其可用于大量患者，尤其是在低收入国家/地区无法接受抗IL-6治疗的患者。但是，将LD-RT用于治疗COVID-19患者的热情尚未减弱。

结论

在这篇综述中，我们研究了LD-RT在非恶性疾病治疗中的作用机制，然后通过研究该方法的阴暗面，我们提供了透彻的讨论，LD-RT是否可能是有前途的治疗方法COVID-19患者的治疗方法。